NCT02498613 2025-09-25
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
12 trialsNCT03649880 2025-03-25
Feasibility of FMISO in Brain Tumors
OHSU Knight Cancer Institute
Phase 2 Recruiting
NCT06087614 2025-01-17
DE-HyART
Rajiv Gandhi Cancer Institute & Research Center, India
Phase 2 Recruiting
NCT01507428 2021-04-29
Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT03303469 2021-02-21
Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging
University of Alabama at Birmingham
Phase 2 Terminated
NCT02471313 2019-04-23
Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00902577 2019-04-08
MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Completed
NCT01868906 2018-08-24
FMISOPETSCS
Dr. Negrin University Hospital
Phase 2 Terminated
NCT01169350 2017-11-17
18F-Fluoromisonidazole and Fludeoxyglucose F 18 PET/CT Patients With Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00559377 2016-12-30
FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02061007 2016-05-09
Biomarker Correlates of Hypoxia in Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Withdrawn
NCT00544674 2012-12-10
PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer
Proacta, Incorporated
Phase 2 Terminated